Maplight Therapeutics, Inc. · NASDAQ:MPLT
Maplight Therapeutics — Investor Presentation (August 2026)
28 slides from Maplight Therapeutics's investor presentation, Aug 13, 2026
Slide 1: Corporate Presentation August 13, 2026
Corporate Presentation August 13, 2026 Exhibit 99.3
Slide 2: Forward-looking statements disclaimer
This presentation and any accompanying oral commentary have been prepared by MapLight Therapeutics, Inc. (“MapLight”, “we,” “us,” “our,” the “Company”, or similar terms) for informational purposes only and not for any other purpose. This presentation contains trademarks, service marks, trade names a
Slide 3: MapLight Therapeutics: Improving Lives of Patients With Debilitating CNS Disorders
MapLight Therapeutics Working to Improve the Lives of Patients Suffering From Debilitating CNS Disorders Novel M1/M4 muscarinic agonist in combination with a peripheral antagonist with a lead indication in schizophrenia, a disease affecting >20 million people globally ~20-35%+ of patients with ASD e
Slide 4: Pipeline programs and anticipated milestones
Program Circuit Indications Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones ML-007C-MA M1/M4 agonist co-formulated with PAC Direct and Indirect Pathways Schizophrenia Engage with FDA at EOP2 meeting Alzheimer’s Disease Psychosis Topline results in 2H 2027 ML-004 5-HT1B/1D agonist Dorsal R
Slide 5: ML-007C-MA Lead Asset in Development for Schizophrenia and ADP
ML-007C-MA Lead Asset in Development for Schizophrenia and ADP
Slide 6: Unmet Need in Schizophrenia Remains
Existing evidence is derived from post hoc or exploratory pooled analyses across two studies Cognitive benefit remains unproven ~30% show no meaningful response to treatment (1) ~40-50% experience an inadequate response to standard of care (1) ~70% discontinue oral therapies within 18 months, often
Slide 7: ZEPHYR Phase 2 results summary
Met the primary endpoint on PANSS Total Score (ES=0.37), with a stronger effect in completers in which there are no modelled assumptions of missing data (ES=0.50) Achieved significance on CGI-S and PANSS Positive Marder Factor Statistically Significant Across Complementary Measures Prespecified Cogn
Slide 8: Primary Endpoint: PANSS Total Score
LS Mean CFB (SE) in PANSS Total Score Primary Endpoint: PANSS Total Score 210/3 mg BID Met Primary Endpoint Change From Baseline in PANSS Total Score (LS Mean Difference) *p<0.05 LS = least squares; SE = standard error. Note: Negative treatment deltas favor active treatment; effect size presented as
Slide 9: PANSS Total Score: Prespecified Completer Analysis
Week 1 Week 2 Week 3 Week 4 Week 5 Primary Endpoint: PANSS Total Score Robust Effect Demonstrated in Prespecified Completer Analysis Change From Baseline in PANSS Total Score (LS Mean Difference) LS Mean CFB (SE) in PANSS Total Score *p<0.05, **p<0.01 MMRM= Mixed model for repeated measures. Note: N
Slide 10: Key Secondary Endpoint: CGI-S
Key Secondary Endpoint: CGI-S Significant Improvement Corroborates PANSS Improvement Change From Baseline in CGI-S (LS Mean Difference) LS Mean CFB (SE) in CGI-S Clinically meaningful and statistically significant improvement in CGI-S vs. placebo at Week 5 0.38-point improvement -0.75 active vs. -0.
Slide 11: PANSS Positive Symptoms
Change From Baseline in PANSS Positive Symptoms (LS Mean Difference) *p<0.05 , **p<0.01 Note: Negative treatment deltas favor active treatment; effect size presented as an absolute value. Analysis based on the mITT population. PANSS Positive Symptoms Significant Improvement in PANSS Positive Marder
Slide 12: Pre-specified Cognitive Composite Score Results
Pre-specified Cognitive Composite Score Results Cognitive Composite Score CFB to Week 5 PANSS Total Score CFB to Week 5 Cognitive Composite Score Placebo 210/3 mg BID N with baseline impairment N=37 N=31 LS Mean Change from Baseline 0.11 0.55 LS Mean Difference vs. Placebo 0.44 P-value p=0.041 Effec
Slide 13: Implications of Cognitive Signal Beyond ZEPHYR
Implications of Cognitive Signal Beyond ZEPHYR Supports Rationale for VISTA and Broader Development Cognitive impairment is estimated to affect >80% of patients with schizophrenia (1) Cognitive impairment is a major determinant of long-term functional outcomes, including employment, independent livi
Slide 14: 210/3 mg BID Effect Across Multiple Endpoints and Symptom Domains
210/3 mg BID Demonstrated Effect Across Multiple Endpoints and Symptom Domains N Active / PBO LS Mean Difference [95% CI] Effect Size P-value PANSS Total Score – mITT 93 / 103 0.37 0.015 PANSS Total Score - Completers 73 / 88 0.50 0.002 CGI-S 93 / 103 0.48 0.002 Cognitive Composite 31 / 37 0.51 0.04
Slide 15: ML-007C-MA Was Generally Well Tolerated
ML-007C-MA Was Generally Well Tolerated Single serious adverse event occurred in placebo arm was worsening schizophrenia. Adverse events, primarily cholinergic in nature, were mostly mild No serious or drug-related severe TEAEs occurred with either dose (1) The only severe TEAE (pneumonia) was asses
Slide 16: Rates of TEAEs With BID Dosing
Placebo N=104 210/3 mg BID N = 99 Mild Moderate Mild Moderate Nausea 6% 0 20% 9% Vomiting 1% 2% 9% 4% Dyspepsia (3) 0 1% 8% 1% Constipation 3% 0 8% 1% Abdominal pain (3) 3% 0 6% 3% Diarrhea 1% 0 5% 0 GERD 2% 0 2% 0 Rates of TEAEs With BID Dosing GI TEAEs ≥2% in Active Arm and > Placebo Most Adverse
Slide 17: Rates of TEAEs for Cobenfy in Pivotal Studies
EMERGENT-2 EMERGENT-3 Placebo Active Placebo Active Discontinuations Due to TEAE 5.6% (2) 7.1% (2) 5.5% (3) 6.4% (3) Due to GI TEAE Not reported 3.2% (4) Not reported 3.2% (4) Utilization of Lower Dose Dose Reduction Due to TEAE(1) 0 5.6% 0.8% 0.8% Inability to Reach Target Dose 1.6% (2) 17.5% (2) 9
Slide 18: Significant Opportunity for New Therapies
PANSS Total Score: Standardized Effect Sizes (Cohen’s d) Peak Sales (Year) (1) $5.0B $3.2B $3.4B $5.8B $6.2B $2.0B $4.3B $6.0B $2.6B (2010) (2036E) (2007) (2011) (2013) (2020) (2028E) (2039E) (2027E) Significant Opportunity for New Therapies 210/3 mg BID Effect Size Falls Within the Range of Approve
Slide 19: ML-007C-MA Target Product Profile Potential Differentiation
Program Mechanism of Action Efficacy in RCTs 210/3 mg BID hit primary endpoint Cognitive Improvement Prespecified secondary endpoint Tolerability/Safety Meaningfully lower rates of significant side effects No Fasting Requirement Taken with food Simple Titration One-dose titration Dosing Frequency QD
Slide 20: Phase 3 Program and Path to NDA Submission
Phase 3 Program and Path to NDA Submission Confirmatory Pivotal Trial Expected to Support Initial Approval Trial in ADP patients evaluating 210/3 mg BID (potentially registrational) On track, supported by ZEPHYR's prespecified cognitive signal Ongoing VISTA (Study 221) Topline results expected in 2H
Slide 21: ML-007 Positioning: Efficacy, Tolerability, Real-World Dosing
ML-007 Positioning: Clinically Meaningful Symptom Improvement, Well Tolerated, Built for Simple, Real-World Dosing Consistent, clinically meaningful benefit across PANSS, global measures, and responder analyses Effect size of 0.37 in mITT and 0.50 among study completers Prespecified cognitive benefi
Slide 22: ML-004 5-HT1B/1D Agonist in Development for Autism Spectrum Disorder
ML-004 5-HT1B/1D Agonist in Development for Autism Spectrum Disorder (ASD)
Slide 23: Unmet Need in ASD Irritability Remains High
Unmet Need in ASD Irritability Remains High ~830K adolescents diagnosed with ASD (U.S., 2039E) (1) ~20-35%+ experience clinically significant irritability or aggression (2) 1 in 6 young people with ASD receive antipsychotics (3) Only 2 approved therapies both with warnings and precautions relevant t
Slide 24: Irritability Outcomes
Irritability Outcomes Includes Subjects with ABC-I >16 at Baseline ABC-I Subscale (1) Care partner-reported CGI-I Irritability Domain (2) Clinican-reported Two measures of irritability assessed by different raters LS Mean Difference vs. Placebo (95% CI), by Scale and Age Group Total N = 26 Adolescen
Slide 25: ML-004 Potential to Address Unmet Needs Through Established Development Path
ML-004 Has the Potential to Address Unmet Needs Through Established Development Path ML-004 demonstrated clinically meaningful improvements in irritability in adolescents with moderate or greater baseline irritability across both caregiver- and clinician-rated scales ABC-I (effect size of 1.33, nomi
Slide 26: Appendix
<> MapLight \ppendix
Slide 27: ZEPHYR Study Outline
Screening Period (Day -7 to -1) Blinded Treatment Period (Day 1 to 35) Follow-up Period (Day 36 to 42) Week 1 Week 2 Week 3 Week 4 Week 5 N = 307 Randomized 1:1:1 Sites: 25 (US only) Placebo Ÿ (N=104) ML-007C-MA Ÿ 330/6 mg QD (1) Ÿ (N=102) ML-007C-MA Ÿ 210/3 mg BID (1) Ÿ (N=101) Primary Endpoint Stu
Slide 28: VISTA Study Outline
Screening Period (Day -35 to -1) Blinded Treatment Period (Day 1 to 49) Follow-up Period (7 + 2 days after last dose) Week 1 Week 2 Week 3 Week 5 Week 7 ML-007C-MA 210/3mg BID (n=150) Primary Endpoint Week 1 105/1.5mg BID Weeks 2-7 210/3mg BID (1) Placebo BID (n=150) N = 300 Randomized 1:1 Sites: 10
MapLight Therapeutics — Investor Presentation (August 2026) on 6ix